Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Buraczewska, Agnieszka" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Tytuł:
    Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review
    Autorzy:
    Buraczewska, Agnieszka
    Kardas, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1065282.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    everolimus
    interstitial lung disease
    metastatic renal cell carcinoma
    Opis:
    We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurred in the form of a drug-induced interstitial lung disease. We also provide a review of the literature concerning opinions on incidence, clinical picture, consequences and management of the complication discussed.
    Źródło:
    OncoReview; 2015, 5, 3; A117-121
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature
    Autorzy:
    Buraczewska, Agnieszka
    Kardas, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1064903.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    molecular targeted therapies
    papillary renal cell carcinoma
    Opis:
    Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted therapies, which are about the progress in clear cell carcinoma. We present an overview of the treatment trials and report a casuistic case of metastatic disease controlled for several years with pazopanib.
    Źródło:
    OncoReview; 2016, 6, 2; A62-65
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Maintenance chemotherapy with pemetrexed in patients with malignant pleural mesothelioma – case series and review of the literature
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/1064851.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    maintenance therapy
    pemetrexed
    pleural mesothelioma
    Opis:
    Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. Surgical complete resection, which is the only radical therapy available, is only possible in a minority of patients who suffer from a locally advanced disease. Radiotherapy can be considered as an adjuvant therapy after surgery or as supportive treatment in palliative care. Attempts are also made at combining it with chemotherapy. In cases of locally advanced, non-resectable or metastatic disease, chemotherapy remains the treatment of choice. The most effective palliative chemotherapy is the pemetrexed plus cisplatin regimen. We describe 3 cases of patients who underwent standard palliative chemotherapy with pemetrexed and cisplatin, manifesting good radiological and clinical response, followed by maintenance therapy with pemetrexed. The use of pemetrexed maintenance therapy helped achieve many years of disease control with acceptable toxicity. The consecutive stages of therapy were continuously discussed with our patients, and their informed consent was obtained. Pemetrexed maintenance therapy is not a standard procedure, but recent findings suggest it may be an efficacious option to consider in selected groups of patients. Further randomized prospective studies are needed, but a limiting factor is the rarity of the disease.
    Źródło:
    OncoReview; 2016, 6, 3; A128-133
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib-sorafenib sequence
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/1065215.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    clear cell carcinoma
    mTOR inhibitor (mTORi)
    metastatic renal cell cancer
    overall survival (OS)
    progression free survival (PFS)
    tyrosine kinase inhibitor (TKI)
    Opis:
    We presented a 39-year-old male who developed progressive cancer disease 4 years after nephrectomy due to clear cell carcinoma. He was diagnosed with locally reccurence and metastases to the liver, spleen and abdominal muscles. The patient was treated with sunitinib and then after disease progression – with sorafenib. We observed 18 months of cancer control (TKI-TKI). After second progression everolimus was administered. Third line everolimus therapy helped to achieve durable stable disease with PFS 46 months till now (May 2015). The patient remains in very good performance status with minimal toxicity from the regimen. This case illustrates a long term survival for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis. The use of three sequential targeted therapies (TKI – TKI – mTORi) helped to achieve over 5 years or disease control, with rarely seen long-term response to third line treatment (mTORi) – where stabilization is good enough. We discussed therapeutic strategies in metastatic renal cell carcinoma according to the literature and therapeutic possibilities in Poland.
    Źródło:
    OncoReview; 2015, 5, 2; A71-75
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience
    Autorzy:
    Buraczewska, Agnieszka
    Kardas, Joanna
    Młot, Beata
    Solarek, Wojciech
    Waśko-Grabowska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/1062936.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    cabozantinib
    hypothyroidism
    renal cell carcinoma
    Opis:
    Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabozantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
    Źródło:
    OncoReview; 2017, 7, 3; 121-125
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Chrom, Paweł
    Waśko-Grabowska, Anna
    Młot, Beata
    Szczylik, Cezary
    Powiązania:
    https://bibliotekanauki.pl/articles/773534.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    endothelial growth factor receptor
    non-small cell lung cancer
    tyrosine kinase inhibitor
    Opis:
    Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
    Źródło:
    OncoReview; 2017, 7, 2; 92-97
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies